背景:心脏代谢疾病(CMD)是一组相互关联的疾病,包括心力衰竭和糖尿病,增加心血管和代谢并发症的风险。拥有CMD的澳大利亚人数量不断增加,因此需要为管理这些条件的人制定新的策略,例如数字健康干预。数字健康干预措施在支持CMD人群方面的有效性取决于用户使用工具的程度。使用对话代理加强数字健康干预,使用自然语言与人互动的技术,可能会因为它们类似人类的属性而增强参与度。迄今为止,没有系统评价收集有关设计特征如何影响支持CMD患者的对话式代理干预的参与的证据.这项审查旨在解决这一差距,从而指导开发人员为CMD管理创建更具吸引力和有效的工具。
目的:本系统评价的目的是综合有关对话代理干预设计特征及其对管理CMD的人员参与的影响的证据。
方法:审查是根据Cochrane干预措施系统审查手册进行的,并根据PRISMA(系统审查和荟萃分析的首选报告项目)指南进行报告。搜索将在Ovid(Medline)进行,WebofScience,和Scopus数据库,它将在提交手稿之前再次运行。纳入标准将包括主要研究研究报告对话代理启用的干预措施,包括接触措施,成人CMD数据提取将寻求捕获CMD人群对使用对话代理干预的观点。JoannaBriggs研究所的关键评估工具将用于评估收集的证据的整体质量。
结果:该评论于2023年5月启动,并于2023年6月在国际前瞻性系统评论注册中心(PROSPERO)注册,然后进行标题和摘要筛选。论文全文筛选已于2023年7月完成,数据提取于2023年8月开始。最终搜索于2024年4月进行,然后最终完成审查,手稿于2024年7月提交同行评审。
结论:本综述将综合与对话代理启用的干预设计特征及其对CMD人群参与的影响有关的各种观察结果。这些观察结果可用于指导开发更具吸引力的对话代理干预措施,从而增加了定期使用干预措施的可能性,并改善了CMD健康结果。此外,这篇综述将确定文献中关于参与度如何报告的差距,从而突出了未来探索的领域,并支持研究人员推进对会话代理启用的干预措施的理解。
背景:PROSPEROCRD42023431579;https://tinyurl.com/55cxkm26。
■DERR1-10.2196/52973。
BACKGROUND: Cardiometabolic diseases (CMDs) are a group of interrelated conditions, including heart failure and diabetes, that increase the risk of cardiovascular and metabolic complications. The rising number of Australians with CMDs has necessitated new strategies for those managing these conditions, such as digital health interventions. The effectiveness of digital health interventions in supporting people with CMDs is dependent on the extent to which users engage with the tools. Augmenting digital health interventions with conversational agents, technologies that interact with people using natural language, may enhance engagement because of their human-like attributes. To date, no systematic review has compiled evidence on how design features influence the engagement of conversational agent-enabled interventions supporting people with CMDs. This review seeks to address this gap, thereby guiding developers in creating more engaging and effective tools for CMD management.
OBJECTIVE: The aim of this systematic review is to synthesize evidence pertaining to conversational agent-enabled intervention design features and their impacts on the engagement of people managing CMD.
METHODS: The review is conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and reported in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Searches will be conducted in the Ovid (Medline), Web of Science, and Scopus databases, which will be run again prior to manuscript submission. Inclusion criteria will consist of primary research studies reporting on conversational agent-enabled interventions, including measures of engagement, in adults with CMD. Data extraction will seek to capture the perspectives of people with CMD on the use of conversational agent-enabled interventions. Joanna Briggs Institute critical appraisal tools will be used to evaluate the overall quality of evidence collected.
RESULTS: This review was initiated in May 2023 and was registered with the International Prospective Register of Systematic Reviews (PROSPERO) in June 2023, prior to title and abstract screening. Full-text screening of articles was completed in July 2023 and data extraction began August 2023. Final searches were conducted in April 2024 prior to finalizing the review and the manuscript was submitted for peer review in July 2024.
CONCLUSIONS: This review will synthesize diverse observations pertaining to conversational agent-enabled intervention design features and their impacts on engagement among people with CMDs. These observations can be used to guide the development of more engaging conversational agent-enabled interventions, thereby increasing the likelihood of regular intervention use and improved CMD health outcomes. Additionally, this review will identify gaps in the literature in terms of how engagement is reported, thereby highlighting areas for future exploration and supporting researchers in advancing the understanding of conversational agent-enabled interventions.
BACKGROUND: PROSPERO CRD42023431579; https://tinyurl.com/55cxkm26.
UNASSIGNED: DERR1-10.2196/52973.